Oncology

Latest News

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases.

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com
Novel Biomarkers May Inform Prognosis in SCLC

June 6th 2025

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the COMMANDS study recommended. | Image credit: Drazen - stock.adobe.com
Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

June 6th 2025

young adult cancer | Image credit: Roswell Park Cancer Center
ASCO Sessions Explore Data and Dynamics of Early-Onset Cancer

June 6th 2025

FDA headquarters | Image Credit: - Tada Images- stock.adobe.com
5 Key FDA Approval Dates Mark a Milestone-Filled May

June 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Dr Michael Thompson Outlines Challenges With the Mass Adoption of EHRs, Precision Medicine
July 25th 2018

Dr Michael Thompson Outlines Challenges With the Mass Adoption of EHRs, Precision Medicine

We know that there are a lot of problems with precision medicine and lots of areas that we need to define better, but that shouldn’t stop us from moving forward and trying to optimize the care for our patients, said Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare.
Site Logo
July 25th 2018

Researchers Report Findings on Three Biosimilar Trastuzumab Products

Kelly Davio
During the 2018 American Society of Clinical Oncology’s (ASCO) Annual Meeting, researchers presented findings on 3 biosimilar trastuzumab products: Samsung Bioepis’ SB3, Agmen’s ABP 980, and Biocad’s Herticad.
Second Biosimilar Approved to Treat Neutropenia
July 25th 2018

Second Biosimilar Approved to Treat Neutropenia

Laura Joszt, MA
A second biosimilar to Amgen’s Neupogen, which treats neutropenia, has been approved in the United States. The FDA approved Pfizer’s filgrastim-aafi, which will be sold under the brand name Nivestym. Zarxio (filgrastim-sndz) was the first filgrastim biosimilar approved by the FDA in 2015.
Geography Influences Type of Posttreatment Imaging Received After Early Breast Cancer
July 24th 2018

Geography Influences Type of Posttreatment Imaging Received After Early Breast Cancer

Allison Inserro
A study of over 35,000 women with early-stage breast cancer found that where you live makes a difference in terms of what kind of posttreatment imaging is received, due to geographic variation.
Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast Cancer
July 23rd 2018

Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast Cancer

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, outlines the role of adjuvant therapy in treating patients with HER2-positive breast cancer, as well as the absence of biomarkers in this patient population.
First Targeted Therapy Approved for R/R AML With IDH1 Mutation
July 22nd 2018

First Targeted Therapy Approved for R/R AML With IDH1 Mutation

Laura Joszt, MA
The FDA approved the first targeted therapy for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. In addition, FDA also approved a companion diagnostic to be used to detect the specific mutations in the IDH1 gene.
Global Review Confirms Diabetes Elevates Cancer Risk, Especially in Women
July 22nd 2018

Global Review Confirms Diabetes Elevates Cancer Risk, Especially in Women

Mary Caffrey
While the connection between diabetes and cancer has been known, this study was the first to show that women with diabetes face a higher risk than men with the disease.
Study Finds Acetazolamide May Be Effective in Treating Glioblastoma
July 22nd 2018

Study Finds Acetazolamide May Be Effective in Treating Glioblastoma

Alison Rodriguez
Acetazolamide, sold under the trade name Diamox, is a drug used to treat altitude sickness, glaucoma, epilepsy, heart failure, and seizures. According to a new study, acetazolamide may also be effective in treating the fast-growing brain tumor glioblastoma.
FDA Expands Use of Ribociclib in Breast Cancer
July 20th 2018

FDA Expands Use of Ribociclib in Breast Cancer

Laura Joszt, MA
The FDA has expanded its approval of ribociclib (Kisqali) to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer under 2 new pilot programs to make the development and review of cancer drugs more efficient.
Site Logo
July 19th 2018

Insights on Site-of-Care Cancer Research: Both Quality and Cost Information Are Necessary to Guide Policy

Kavita Patel, MD, MPH A. Mark Fendrick, MD
The implementation of alternative payment models that successfully capture clinical heterogeneity—without adding unacceptable levels of administrative complexity—may be equally (if not more) important than site-neutral payment policies.
Site Logo
July 19th 2018

Differences in Spending on Provider-Administered Chemotherapy by Site of Care in Medicare

Yamini Kalidindi, MHA Jeah Jung, PhD Roger Feldman, PhD
Spending on chemotherapy drugs was lower among Medicare beneficiaries who received chemotherapy in hospital outpatient departments than among comparable beneficiaries receiving chemotherapy in physician offices.
Report Provides Snapshot of Cancer Clinic Performance in Washington State on Quality and Cost
July 18th 2018

Report Provides Snapshot of Cancer Clinic Performance in Washington State on Quality and Cost

Laura Joszt, MA
After 5 years of research, the Hutchinson Institute for Cancer Outcomes Research has released a report that is the first in the nation to publicly report clinic-level quality measures linked to cost in oncology.
Tecentriq–Avastin Combination Earns Breakthrough Therapy Designation for Liver Cancer
July 18th 2018

Tecentriq–Avastin Combination Earns Breakthrough Therapy Designation for Liver Cancer

Samantha DiGrande
Genentech announced yesterday that the FDA has granted Breakthrough Therapy Designation to atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) as a first-line treatment for patients with the most common form of liver cancer, advanced or metastatic hepatocellular carcinoma (HCC).
Sequencing Therapy in NSCLC
July 18th 2018

Sequencing Therapy in NSCLC

Using Antiangiogenic Therapy in NSCLC in the Future
July 18th 2018

Using Antiangiogenic Therapy in NSCLC in the Future

Antiangiogenic Therapy in NSCLC: Addressing the Unknown
July 18th 2018

Antiangiogenic Therapy in NSCLC: Addressing the Unknown

Necitumumab in Squamous NSCLC
July 18th 2018

Necitumumab in Squamous NSCLC

Rationale for Ramucirumab in NSCLC
July 18th 2018

Rationale for Ramucirumab in NSCLC

Pembrolizumab in First-Line Nonsquamous NSCLC
July 18th 2018

Pembrolizumab in First-Line Nonsquamous NSCLC

Antiangiogenic Therapy in NSCLC
July 18th 2018

Antiangiogenic Therapy in NSCLC

Breakthroughs in Treating NSCLC
July 18th 2018

Breakthroughs in Treating NSCLC

Key Points From the REVEL Trial in NSCLC
July 18th 2018

Key Points From the REVEL Trial in NSCLC

Considerations for Antiangiogenic Therapy in NSCLC
July 18th 2018

Considerations for Antiangiogenic Therapy in NSCLC

Evidence for Immunotherapy in Frontline NSCLC
July 18th 2018

Evidence for Immunotherapy in Frontline NSCLC

Future Use of Antiangiogenic Agents in NSCLC
July 18th 2018

Future Use of Antiangiogenic Agents in NSCLC

Immunotherapy and <i>VEGF</i>-Targeted Therapy in NSCLC
July 18th 2018

Immunotherapy and <i>VEGF</i>-Targeted Therapy in NSCLC

VEGF Inhibition in NSCLC
July 18th 2018

VEGF Inhibition in NSCLC

The Phase 3 REVEL Trial in NSCLC
July 18th 2018

The Phase 3 REVEL Trial in NSCLC

Ramucirumab in Relapsed/Refractory NSCLC
July 18th 2018

Ramucirumab in Relapsed/Refractory NSCLC

Bevacizumab in NSCLC
July 18th 2018

Bevacizumab in NSCLC

<1
...
424344454647484950
...
185>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo